2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2053

Efficacy Of Intermittent Intra-Venous Cyclophosphamide and Cyclosporin A Combination Therapy For Rapidly Progressive Interstitial Lung Disease With Dermatomyositis Associated With Anti-Melanoma Differentiation-Associated Gene 5 Autoantibody Titer
Abstract Number: 748

Efficacy Of Methotrexate For Remission Induction and Maintenance In Granulomatosis With Polyangiitis In Routine Clinical Practice
Abstract Number: 743

Efficacy Of Rituximab For Otolaryngologic (ENT) Manifestations Of Granulomatosis With Polyangiitis (GPA, Wegener’s granulomatosis)
Abstract Number: 588

Efficacy Of Rituximab In Patients With Refractory Lupus Nephritis, a Post-Hoc Analysis From Phase II Trial In Japan
Abstract Number: 1571

Efficacy Of Tacrolimus Combination Therapy During The Maintenance Phase Of Systemic Lupus Erythematosus
Abstract Number: 1207

Efficacy Of Tocilizumab In Patients With AA Amyloidosis Secondary To Familial Mediterranean Fever: A Single Centre Experience
Abstract Number: 788

Efficacy Of Tocilizumab In Refractory Adult-Onset Still’s Disease: Multicenter Study Of 32 Patients
Abstract Number: 985

Efficacy Study Of Multimedia To Educate Rheumatoid Arthritis Patients
Abstract Number: 425

Efficacy, Pharmacokinetics, and Safety of Different Doses of Methotrexate in Combination With Adalimumab: Results From the Concerto Trial
Abstract Number: 2665

Efficiency Gains For Rheumatology Consultation From An Electronic Referral System In a Safety Net Health System
Abstract Number: 1595

Electroclinical Correlates and Outcome Of Status Epilepticus In Systemic Lupus Erythematosus
Abstract Number: 962

Electronic Learning Module Enhances Rheumatology Education
Abstract Number: 658

Elevated 8-Isoprostane In Scleroderma: Implications Of Its Role In Inhibiting Vascular Endothelial Growth Factor-Induced Angiogenesis
Abstract Number: 2531

Elevated Combined Serum Free Light Chains Are Associated With Active Disease In Systemic Lupus Erythematosus
Abstract Number: 2024

Elevated IgG4+ Plasmablasts In Patients With Active, Untreated IgG4-Related Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].